HCV NS5A Inhibitors in Development

Clinics in Liver Disease

Volumn 17, Issue 1, 2013, Pages 111-121

  Suk Fong Lok, Anna ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Asunaprevir; Daclatasvir; Direct acting antiviral agents; GS 7977; Hepatitis C; Pegylated interferon; Ribavirin

Indexed keywords

ABT 267; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; GS 5885; GS 9451; GSK 2336805; IDX 719; JNJ 47910382; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PLACEBO; PPI 668; RIBAVIRIN; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL ACTIVITY; BLOOD CELL COUNT; CLINICAL TRIAL; DIARRHEA; DRUG DOSE COMPARISON; DRUG TARGETING; DRUG TOLERABILITY; DRY SKIN; FATIGUE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPANESE; NAUSEA; NONHUMAN; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; IMIDAZOLES; INTERFERON-ALPHA; INTERLEUKINS; ISOQUINOLINES; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84870024853     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.09.006     Document Type: Review

References (21)

1. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
2. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
3. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
4. Bronowicki J.P., Lencioni R., Marrero J., et al. Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC)-+-PR: the PROVIDE study interim results. J Hepatol 2012, 54:S6.
5. Fridell R.A., Qiu D., Wang C., et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010, 54:3641-3650.
6. Gao M., Nettles R.E., Belema M., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010, 465:96-100.
7. Fridell R.A., Wang C., Sun J.H., et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011, 54:1924-1935.
8. Nettles R.E., Gao M., Bifano M., et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011, 54:1956-1965.
9. Bifano M., Sevinsky H., Persson A., et al. BMS-790052 has no effect on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects. Hepatology 2011, 54:991A-992A.
10. Bifano M., Sevinsky H., Persson A., et al. Single-dose pharmacokinetics of BMS-790052 in subjects with hepatic impairment compared with healthy subjects. Hepatology 2011, 54:1004A.
11. Suzuki F., Chayama K., Kawakami Y., et al. BMS-790052, an NS5A replication complex inhibitor, in combination with peginterferon alpha-2b and ribavirin in Japanese treatment-naive and nonresponder patients with chronic HCV genotype 1 infection. Hepatology 2011, 54:1441A.
12. Izumi N., Asahina Y., Yokosuka O., et al. Combination therapy of treatment-naive and nonresponder patients with HCV genotypoe1 infection with BMS-790052, an NS5A replication complex inhibitor, in combination with peginterferon alfa-2a and ribavirin. Hepatology 2011, 54:1439A-1440A.
13. Hezode C., Hirschfield G., Ghesquiere W., et al. BMS-790052, A NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 patients: phase 2B Al444010 study interim week 12 results. Hepatology 2011, 54:474A-475A.
14. Ratziu V., Gadano S., Pol C., et al. Triple therapy with daclatasvir (DCV; BMS-790052), peginterferon alfa-2a and ribavirin in HCV-infected prior null and partial responders: 12-week results of phase 2B COMMAND-2 trial. J Hepatol 2012, 56:S478-S479.
15. Lok A.S., Gardiner D.F., Lawitz E., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012, 366:216-224.
16. Lok A.S., Gardiner D.F., Hezode C., et al. Confirmation that quadruple therapy with daclatasvir (NS5A Inhibitor), asunaprevir (NS3 Inhibitor) and peginterferon/ribavirin results in high rate of SVR4 in HCV genotype 1 null responders. J Hepatol 2012, 56(Suppl 2):S557.
17. Sulkowski M.S., Gardiner D.F., Lawitz F., et al. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor) +/- ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3. J Hepatol 2012, 56(Suppl 2):S560.
18. Chayama K., Takahashi S., Toyota J., et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012, 55:742-748.
19. Suzuki F., Ikeda K., Toyota J., et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1B-infected null responders or ineligible/intolerant to peginterferon/ribavirin. J Hepatol 2012, 56(Suppl 2):S7-S8.
20. Yang G., Wiles J., Patel D., et al. Preclinical characteristics of ACH-3102: a novel HCV NS5A inhibitor with improved potency against genotype-1A virus and variants resistant to 1st generation of NS5A inhibitors. J Hepatol 2012, 56(Suppl 2):S330.
21. Liu R., Kong R., Mann P., et al. In vitro resistance analysis of HCV NS5A inhibitor: MK-8742 demonstrates increased potency against clinical resistance variants and higher resistance barrier. J Hepatol 2012, 56(Suppl 2):S334-S335.